KR102305109B1 - 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 - Google Patents

폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 Download PDF

Info

Publication number
KR102305109B1
KR102305109B1 KR1020207018965A KR20207018965A KR102305109B1 KR 102305109 B1 KR102305109 B1 KR 102305109B1 KR 1020207018965 A KR1020207018965 A KR 1020207018965A KR 20207018965 A KR20207018965 A KR 20207018965A KR 102305109 B1 KR102305109 B1 KR 102305109B1
Authority
KR
South Korea
Prior art keywords
cys
lys
ser
glu
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020207018965A
Other languages
English (en)
Korean (ko)
Other versions
KR20200084064A (ko
Inventor
라빈드라 쿠마르
애시아 그린버그
Original Assignee
악셀레론 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악셀레론 파마 인코포레이티드 filed Critical 악셀레론 파마 인코포레이티드
Priority to KR1020217029755A priority Critical patent/KR20210119546A/ko
Publication of KR20200084064A publication Critical patent/KR20200084064A/ko
Application granted granted Critical
Publication of KR102305109B1 publication Critical patent/KR102305109B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207018965A 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 Expired - Fee Related KR102305109B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217029755A KR20210119546A (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462007908P 2014-06-04 2014-06-04
US62/007,908 2014-06-04
KR1020207003791A KR102132144B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
PCT/US2015/034245 WO2015187977A1 (en) 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003791A Division KR102132144B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029755A Division KR20210119546A (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Publications (2)

Publication Number Publication Date
KR20200084064A KR20200084064A (ko) 2020-07-09
KR102305109B1 true KR102305109B1 (ko) 2021-09-27

Family

ID=54767384

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207018965A Expired - Fee Related KR102305109B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020207003791A Expired - Fee Related KR102132144B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020177000297A Expired - Fee Related KR102077286B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020217029755A Ceased KR20210119546A (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207003791A Expired - Fee Related KR102132144B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020177000297A Expired - Fee Related KR102077286B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020217029755A Ceased KR20210119546A (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Country Status (12)

Country Link
US (2) US10023621B2 (https=)
EP (2) EP3152237B1 (https=)
JP (3) JP6568110B2 (https=)
KR (4) KR102305109B1 (https=)
CN (2) CN106795224B (https=)
AU (2) AU2015269333B2 (https=)
BR (1) BR112016028520A2 (https=)
CA (1) CA2950754C (https=)
EA (2) EA035455B1 (https=)
MA (2) MA51074A (https=)
MX (2) MX382908B (https=)
WO (1) WO2015187977A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
AU2009262970A1 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
EA201590719A1 (ru) 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
US10023621B2 (en) 2014-06-04 2018-07-17 Acceleron Pharma Inc. Follistatin-related fusion proteins
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
AU2016238254B2 (en) * 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2017152090A2 (en) * 2016-03-04 2017-09-08 Shire Human Genetic Therapies, Inc. Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
US10905766B2 (en) 2017-03-23 2021-02-02 Oregon State University Therapeutic compositions and methods for treatment of muscle wasting diseases
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
CN108218985B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用
CN111936617A (zh) * 2018-03-16 2020-11-13 益缪索夫特公司 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法
CN111902157B (zh) * 2018-03-21 2023-08-04 松阳生技股份有限公司 促进局部肌肉增长、减缓或防止局部肌肉萎缩的组合物及其用途
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
WO2019222690A1 (en) * 2018-05-17 2019-11-21 Hmi, Inc. Inhibition of follistatin
US12246042B2 (en) 2018-08-29 2025-03-11 Myos Corp. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
AU2022214780A1 (en) * 2021-01-26 2023-09-07 Immunis, Inc. Molecular superstructure and methods of use thereof
AU2023291641A1 (en) 2022-06-15 2024-12-12 Five Prime Therapeutics, Inc. Fusion protein for the prevention, treatment or amelioration of kidney diseases
IL317593A (en) 2022-06-15 2025-02-01 UCB Biopharma SRL Follistatin-FC fusion proteins
WO2024121351A1 (en) * 2022-12-07 2024-06-13 Lodberg Andreas Extracellular matrix binding compounds for the localized loading of therapeutic or diagnostic agents
WO2025157262A1 (en) * 2024-01-25 2025-07-31 Sichuan Real & Best Biotech Co., Ltd. Nucleic acids encoding follistatin and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012070739A (ja) * 2004-07-23 2012-04-12 Acceleron Pharma Inc ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
DE69233480T2 (de) * 1991-02-08 2006-01-05 Progenics Pharmaceuticals, Inc. CD4-gamma2- und CD4-IgG2-Chimären
CA2144081C (en) 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
AU772694B2 (en) 1999-01-21 2004-05-06 Metamorphix International, Inc. Growth differentiation factor inhibitors and uses therefor
EP1174149A1 (en) 1999-04-19 2002-01-23 Kyowa Hakko Kogyo Co., Ltd. Proliferation inhibitor for androgen-independent tumor
WO2001009368A1 (en) 1999-07-30 2001-02-08 The General Hospital Corporation Follistatin antagonists
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
CN1993048A (zh) * 2002-02-21 2007-07-04 惠氏公司 包含促滤泡素抑制素结构域的蛋白质
CA2476887A1 (en) 2002-02-21 2003-09-04 Wyeth Gasp1:a follistatin domain containing protein
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
ATE474593T1 (de) 2003-03-21 2010-08-15 Celldex Therapeutics Ltd Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway
BRPI0410927A (pt) 2003-06-02 2006-06-27 Wyeth Corp métodos terapêuticos e profiláticos para distúrbios neuromusculares
WO2005025601A1 (en) 2003-09-15 2005-03-24 Monash University Follistatin isoforms and uses thereof
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
JP2007507429A (ja) 2003-10-06 2007-03-29 モナシュ ユニバーシティー 治療方法
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
JP2009518422A (ja) * 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
CA2693178C (en) 2006-11-29 2018-12-04 Nationwide Children's Hospital, Inc. Myostatin inhibition for enhancing muscle and/or improving muscle function
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
DK2124999T3 (da) 2006-12-18 2013-01-14 Acceleron Pharma Inc Activin-actrii antagonister og anvendelser til behandling af anæmi
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP5773868B2 (ja) * 2008-06-26 2015-09-02 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
AU2009262970A1 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
JP5813114B2 (ja) * 2010-08-25 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｌ−１８ｒ１に対する抗体およびその使用
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP2844271B1 (en) 2012-05-17 2018-02-28 Paranta Biosciences Limited Use of follistatin or of an activin inhibitor for preventing or treating tissue graft dysfunction
AU2013281328B2 (en) * 2012-06-27 2017-11-23 MeiraGTx Gene Regulation Limited Combination for treating an inflammatory disorder
EA201590719A1 (ru) * 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives
US10023621B2 (en) * 2014-06-04 2018-07-17 Acceleron Pharma Inc. Follistatin-related fusion proteins
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
AU2016238254B2 (en) * 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
JP2020519291A (ja) 2017-05-12 2020-07-02 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012070739A (ja) * 2004-07-23 2012-04-12 Acceleron Pharma Inc ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物

Also Published As

Publication number Publication date
EP3152237A4 (en) 2017-11-01
MX2021006017A (es) 2021-07-06
EP3152237A1 (en) 2017-04-12
JP2019203017A (ja) 2019-11-28
CN106795224B (zh) 2021-05-18
US10023621B2 (en) 2018-07-17
EA202090632A1 (ru) 2020-07-31
AU2015269333B2 (en) 2020-05-07
US10954279B2 (en) 2021-03-23
US20160185836A1 (en) 2016-06-30
JP2017518303A (ja) 2017-07-06
JP6568110B2 (ja) 2019-08-28
CA2950754A1 (en) 2015-12-10
EA035455B1 (ru) 2020-06-18
MA51075A (fr) 2020-10-14
CA2950754C (en) 2021-10-26
EP3721892A1 (en) 2020-10-14
KR20200017548A (ko) 2020-02-18
US20180340013A1 (en) 2018-11-29
AU2015269333A1 (en) 2016-12-15
AU2020210315A1 (en) 2020-08-27
KR102132144B1 (ko) 2020-07-09
KR20200084064A (ko) 2020-07-09
MX2016015868A (es) 2017-04-05
KR20210119546A (ko) 2021-10-05
CN113583104A (zh) 2021-11-02
KR20170005891A (ko) 2017-01-16
JP6856716B2 (ja) 2021-04-07
CN106795224A (zh) 2017-05-31
EA201692529A1 (ru) 2017-05-31
JP2021095416A (ja) 2021-06-24
MA51074A (fr) 2020-10-14
KR102077286B1 (ko) 2020-02-13
EP3721892B1 (en) 2024-05-22
WO2015187977A1 (en) 2015-12-10
EP3152237B1 (en) 2020-04-01
BR112016028520A2 (pt) 2017-10-24
MX382908B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
KR102305109B1 (ko) 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
US20220281951A1 (en) Variants derived from actriib and uses therefor
AU2010322011B2 (en) ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US11497792B2 (en) Methods for treatment of Duchenne muscular dystrophy with follistatin polypeptides
HK1236544A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1238658B (zh) 用促滤泡素抑制素多肽治疗病症的方法和组合物
HK1236544B (en) Methods and compositions for treatment of disorders with follistatin polypeptides

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240917

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240917